Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 TrialShoji Nagao, Takayuki Enomoto, Kouji Yamamoto et al.|NEJM Evidence|2023Cited by 31
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathwayNozomu Yanaihara, Aikou Okamoto|Gynecologic Oncology|2022Cited by 15
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathwayYasushi Iida, Aikou Okamoto|Frontiers in Oncology|2024Cited by 13
<i>MicroRNA-34a</i>/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinomaRyo Yokomizo, Aikou Okamoto|Oncotarget|2019Cited by 10
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathwayYasushi Iida, Aikou Okamoto|Research Square|2023Cited by 0